The stocks of MRNA have been issued a rating of hold by around twenty different brokerages that have been covering the firm. According to a report, three of the analysts gave the company a rating of sell, while six of them have given it a rating of hold. Eight other analysts gave the company a rating of buy. Currently, the price target of the company has been set at $157.94.
The Stock Commentary of MRNA
There have been quite a few research equities that have commented on the stocks of MRNA. Zacks Investment Research has already increased the stocks of the company with a rating from sell to hold with a price target set at $166 in a 4th December research report. SVB Leerink has also increased the price target of the company from $69 to $80 with a rating of underperform in a 1st February research report.
Chardan Capital has also increased the price target from $107 to $182 with a rating of buy in an 8th March research report. The Goldman Sachs Group has also put up a rating of buy with a price target set at $139 in an 11th December research note. In the end, Wells Fargo & Company has also increased the price target of the company from $129 to $145.
The stocks of MRNA traded on Friday at $132.55. The quick ratio of the company is 2.43, with a 2.43 current ratio along with a 0.04 debt-to-equity ratio. The moving average price of the company over a period of 50-days is $148.13, while the moving average price of the company over 200 days is $118.59. The market cap of the firm is $53.09 billion, with a -81.82 PE ratio, and a 0.53 PEG ratio. The year low of the company is $29.84, with a year high of around $189.26.
